Clinical trial · Interventional
Safety and Efficacy of Atiprimod for Patients With Refractory Multiple Myeloma
An Open-Label Study of the Safety and Efficacy of Atiprimod Treatment for Patients With Refractory or Relapsed Multiple Myeloma
NCT00086216CI-TRIAL-00001052completedPhase 1 / Phase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a Phase I/IIa clinical trial to identify the maximum tolerated dose of atiprimod and to evaluate the safety of atiprimod in patients with refractory or relapsed multiple myeloma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Atiprimod | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- The primary objective of this study is to identify the maximum tolerated dose
- timeFrame
- 1 year
Secondary outcomes (1)
- measure
- The secondary objective of this study is to measure the pharmacokinetics of
- timeFrame
- 1 year
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * documented history of multiple myeloma, * failed at least two prior regimens for multiple myeloma, * 18 years of age or older, * ECOG(Zubrod)PS of 0 to 2, * screening evaluation for determining eligibility prior to enrollment, * signed informed consent form, Exclusion Criteria: * concomitant therapy medications including corticosteroids or other chemotherapy that is or may be active against myeloma , * renal insufficiency (serum creatinine levels of \> 2mg/dL), * mucosal bleeding, * any condition which in the opinion of the Investigator, places the patient at unacceptable risk if he/she were to participate in the study. * clinically relevant active infection or co-morbid medical conditions. * prior malignancy(within the last 3 years) except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer for which the patient is has been disease-free for at least 3 years. * patients with non-secretory myeloma. * as atiprimod is a potent inhibitor or CYP2D6, patients taking drugs that are substrates of CYP2D6(e.g. beta blockers, antidepressants and antipsychotics) will be excluded.
References
Publications (0)
Data not yet available
No reference posted for this study.